Thrombocytosis in myeloproliferative disease

Thrombocytosis in myeloproliferative disease is a hematologic condition defined by a sustained, autonomous overproduction of circulating platelets resulting from an underlying clonal stem cell neoplasm, most commonly essential thrombocythemia, polycythemia vera, or primary myelofibrosis

Thrombocytosis in myeloproliferative disease is a hematologic condition defined by a sustained, autonomous overproduction of circulating platelets resulting from an underlying clonal stem cell neoplasm, most commonly essential thrombocythemia, polycythemia vera, or primary myelofibrosis It primarily affects the hematopoietic system in adults, driven by somatic driver mutations—most notably in JAK2, CALR, or MPL—that cause cytokine-independent megakaryocyte proliferation in the bone marrow

It primarily affects the hematopoietic system in adults, driven by somatic driver mutations—most notably in JAK2, CALR, or MPL—that cause cytokine-independent megakaryocyte proliferation in the bone marrow Clinically, it is characterized by peripheral platelet counts exceeding 450,000/µL and carries a marked predisposition to microvascular disturbances, arterial or venous thromboembolism, splenomegaly, and paradoxical mucocutaneous bleeding due to acquired von Willebrand syndrome at extremely el...

Clinically, it is characterized by peripheral platelet counts exceeding 450,000/µL and carries a marked predisposition to microvascular disturbances, arterial or venous thromboembolism, splenomegaly, and paradoxical mucocutaneous bleeding due to acquired von Willebrand syndrome at extremely elevated counts

Clinically, it is characterized by peripheral platelet counts exceeding 450,000/µL and carries a marked predisposition to microvascular disturbances, arterial or venous thromboembolism, splenomegaly, and paradoxical mucocutaneous bleeding due to acquired von Willebrand syndrome at extremely elevated counts